Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin.

The pharmacogenomics journal - 1 Jun 2016

Kjersem J B, Thomsen M, Guren T, Hamfjord J, Carlsson G, Gustavsson B, Ikdahl T, Indrebø G, Pfeiffer P, Lingjærde O, Tveit K M, Wettergren Y, Kure E H

Abstract excerpt

The objective of the study was to investigate whether specific single nucleotide polymorphisms (SNPs) with influence on drug transport, biotransformation and repair mechanisms are associated with treatment outcome and toxicity in metastatic colorectal cancer (mCRC). We genotyped blood samples from 519 mCRC patients treated with first-line 5-fluorouracil and oxaliplatin +/- cetuximab for 17 SNPs in 10 genes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials, Phase III as Topic
Share to Multidrug Resistance-Associated Protein 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Organoplatinum Compounds

Share to Oxaliplatin

Share to Pharmacogenomic Variants

Share to Scandinavian and Nordic Countries

Share to Transaminases

Share to Xeroderma Pigmentosum Group D Protein

Source

Identifiers

PMID: 26261061
DOI: 10.1038/tpj.2015.54

Genes

AGXT
ERCC2
ABCC1
ABCC2
ERCC1
GSTP1
MSH6
XRCC1
XRCC3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin.PMID 26261061Read ↗

A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen.Semantic proximity Read ↗

Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy.Semantic proximity Read ↗

Validation of Genetic Markers Associated with Survival in Colorectal Cancer Patients Treated with Oxaliplatin-Based Chemotherapy.Semantic proximity Read ↗

Genetic variants in DNA repair genes as potential predictive markers for oxaliplatin chemotherapy in colorectal cancer.Semantic proximity Read ↗

Association of DNA repair gene variants with colorectal cancer: risk, toxicity, and survival.Semantic proximity Read ↗

Association of DNA repair gene variants with colorectal cancer: risk, toxicity, and survivalSemantic proximity Read ↗

Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741.Semantic proximity Read ↗

Pharmacogenetics of oxaliplatin as adjuvant treatment in colon carcinoma: are single nucleotide polymorphisms in GSTP1, ERCC1, and ERCC2 good predictive markers?Semantic proximity Read ↗

Polymorphisms of GSTP1, ERCC2 and TS-3′UTR are associated with the clinical outcome of mFOLFOX6 in colorectal cancer patientsSemantic proximity Read ↗

SNPs in transporter and metabolizing genes as predictive markers for oxaliplatin treatment in colorectal cancer patients.Semantic proximity Read ↗

Genetic variants as potential predictive biomarkers in advanced colorectal cancer patients treated with oxaliplatin‐based chemotherapySemantic proximity Read ↗

Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.